VRAX • NASDAQ
Virax Biolabs Group Limited
$6.36
Stock Details
| Market Cap | 1,186,935 |
|---|---|
| Day Change | 3.18 (100.00%) |
| Volume | 71,417,490 |
| Avg Volume | 1,148,924 |
| Price Range | 2.5-28.5 |
Overview
| Country | GB |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
Company Profile
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Financial Overview
| 52 Week High | 28.5 |
|---|---|
| 52 Week High Date | 2025-07-21 |
| 52 Week Low | 2.5 |
| 52 Week Low Date | 2026-04-10 |
| 10D Avg Trading Vol | 7.50037 |
| YTD Price Return Daily | -26.3889 |
| MTD Price Return Daily | 116.3265 |
Cash Flow
| TTM/Share | |
|---|---|
| Annual/Share | -1.1901 |
| Quarterly/Share | -0.9021 |
Price-to-Earnings
| Annual Ratio | 7.2691 |
|---|---|
| Quarterly Ratio | 11.3537 |
| TTM |
Revenue
| 3Y Growth | |
|---|---|
| 5Y Growth | -42.42 |
| Annual/Share | -67.47 |
| TTM/Share | 0.0006 |
| 5Y Share Growth | -28.02 |
Earnings Per Share
| Annual | -1.6248 |
|---|---|
| 3Y Growth | |
| 5Y Growth | |
| Quarterly YOY Growth |
Price-to-Book
| Ratio | 0.9103 |
|---|---|
| Annual Ratio | 0.869 |
| TTM | 0.7491 |